<DOC>
	<DOCNO>NCT01891331</DOCNO>
	<brief_summary>CYP51 enzyme essential fungal growth . Inhibition CYP51 result accumulation compound toxic fungus . CYP51 target class drug refer 'azole antifungal ' . The lack selectivity azole antifungal responsible many side effect associate drug . VT-1161 design safer active fungal specie typically responsible vaginal yeast infection ( i.e . vulvovaginal candidiasis )</brief_summary>
	<brief_title>A Study Evaluate Oral VT-1161 Treatment Patients With Acute Vaginal Candidiasis ( Yeast Infection )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Key Females ≥18 &lt; 65 year Clinical diagnosis symptomatic acute VVC Positive KOH .At least one vulvovaginal sign ( vulvovaginal erythema , edema , excoriation ) . At least one vulvovaginal symptom ( vulvovaginal itching , burning , irritation ) A minimum composite vulvovaginal sign symptom score ≥6 must able swallow capsule Evidence major organ system disease History cervical cancer History diabetes mellitus Pregnant Recent use systemic antifungal drug systemic antimicrobial therapy reason Recent use drug treat vaginal infection Recent use immunosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>